Rank #1786ACRV

Acrivon Therapeutics, Inc.

$1.58

-0.63% (Daily)

Market Cap

$49.86M

Revenue

$N/A

Rank by MCap

#1786

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Peter Blume-Jensen M.D., Ph.D.

Headquarters

Watertown, MA

Employees

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from i...